The DOI matches its Crossref record; 50 of the 50 references it cites were found in a registry or an index.
The association of aspirin use with overall survival of patients with inoperable non-small cell lung cancer: a retrospective study
Open accessAbstract
Background: Studies have indicated that individuals taking aspirin have a reduced risk of cancers and have also established chemo-preventive benefit of aspirin in colorectal cancer. However, research on the association between aspirin use and the survival in patients with lung cancer has revealed inconsistent results. In this study, we investigated the effect of aspirin use on the survival of inoperable non-small cell lung cancer (NSCLC) patients. Methods: We identified a cohort of 38,842 patients diagnosed with NSCLC between 2000 and 2012 using the Taiwan’s National Health Insurance Research Database and used propensity score matching to reduce possible confounding factors. In total, 9864 patients (4932 matched pairs) were included in the matched cohort. Aspirin exposure was analyzed to identify a possible association with mortality in patients with inoperable NSCLC. Time-dependent Cox regression models were used to calculate the hazard ratios (HRs) and the 95% confidence intervals (95% CIs) that corresponded with aspirin exposure. Results: A total of 4979 patients used aspirin at the time of diagnosis of NSCLC. The median overall survival (OS) of the aspirin users was 1.73 (interquartile range, 0.94–3.53) years compared with the 1.30 (interquartile range, 0.69–2.62) years of the non-aspirin users. The Cox proportional hazard model with the time-dependent covariate revealed that aspirin use was associated with a significantly longer OS (HR: 0.83, 95.0% CI: 0.80–0.86). After controlling the sociodemographic characteristics (age, sex, income, and level of urbanization) and lung cancer treatments by propensity score matching, the aspirin users still had a significantly longer OS than the non-aspirin users (HR: 0.79, 95.0% CI: 0.75–0.83). Conclusion: Aspirin use is associated with a longer OS in patients with inoperable NSCLC, suggesting that aspirin has a potential anticancer effect. These results warrant further randomized clinical trials to evaluate the actual role of aspirin in the treatment of NSCLC patients.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures



Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Sung, H., Ferlay, J., Siegel, R. L., Laversanne, M., Soerjomataram, I., Jemal, A., & Bray, F. (2021) · CA: A Cancer Journal for Clinicians · doi:10.3322/caac.21660 · Cited by 108,699 · cited 1×
“4% of all cancer cases) worldwide in 2020 [1].”
BackgroundInhibition of Prostaglandin Synthesis as a Mechanism of Action for Aspirin-like Drugs
VANE, J. R. (1971) · Nature New Biology · doi:10.1038/newbio231232a0 · Cited by 8,605 · cited 4×
“Notably, the anti-neoplastic effect of aspirin was mediated through its inhibition of COX enzymes that promote carcinogeneis through the synthesis of PG. [44] Apart from inhibiting the synthesis of PG, aspirin has also been shown to upregulate tumor-suppression genes and inhibit NF-kB activation, thus illustrating its…”
BackgroundInfluentialRothwell, P. M., Fowkes, F. G. R., Belch, J. F., Ogawa, H., Warlow, C. P., & Meade, T. W. (2011) · The Lancet · doi:10.1016/s0140-6736(10)62110-1 · Cited by 1,497 · cited 1×
“89) [41], which is consistent with the result of our study, which showed that aspirin use is associated with an improved OS in inoperable NSCLC patients.”
ResultRothwell, P. M., Wilson, M., Elwin, C.-E., Norrving, B., Algra, A., Warlow, C. P., & Meade, T. W. (2010) · The Lancet · doi:10.1016/s0140-6736(10)61543-7 · Cited by 1,351 · cited 1×
“Nonetheless, further studies established the chemopreventive effect of aspirin in colorectal cancer [32, 33] and these inspired numerous studies on the potential preventive role of aspirin on other cancers [34–36], contributing to the publication of abundant systematic reviews and meta-analyses [37–39].”
BackgroundValidation of the national health insurance research database with ischemic stroke cases in Taiwan
Cheng, C., Kao, Y. Y., Lin, S., Lee, C., & Lai, M. L. (2011) · Pharmacoepidemiology and Drug Safety · doi:10.1002/pds.2087 · Cited by 1,277 · cited 1×
“The diagnostic accuracy of the NHIRD has been validated previously for major diseases [23], and its clinical consistency in cancer research had been proved [24].”
Taiwan’s National Health Insurance Research Database: past and future
Hsieh, C.-Y., Su, C.-C., Shao, S.-C., Sung, S.-F., Lin, S.-J., Yang Kao, Y.-H., & Lai, E. C.-C. (2019) · Clinical Epidemiology · doi:10.2147/clep.s196293 · Cited by 1,213 · cited 1×
“Therefore, the diagnosis of cancer can be considered to be accurate [25].”
BackgroundSelf-citationRandomised trial of prophylactic daily aspirin in British male doctors
Peto, R., Gray, R., Collins, R., Wheatley, K., Hennekens, C., Jamrozik, K., Warlow, C., Hafner, B., Thompson, E., Norton, S., et al. (1988) · BMJ · doi:10.1136/bmj.296.6618.313 · Cited by 1,166 · cited 1×
“While a case-control study of 700 patients with colorectal cancer conducted in Melbourne, Australia was the first to show a possible anti-cancer effect in human cancer [9], randomized controlled trials showed no association between aspirin use and cancer incidence [11, 30, 31].”
BackgroundWu, C.-Y., Chen, Y.-J., Ho, H. J., Hsu, Y.-C., Kuo, K. N., Wu, M.-S., & Lin, J.-T. (2012) · JAMA · doi:10.1001/2012.jama.11975 · Cited by 818 · cited 1×
“This definition was used in a previous study [26].”
MethodEffect of Aspirin on All-Cause Mortality in the Healthy Elderly
McNeil, J. J., Nelson, M. R., Woods, R. L., Lockery, J. E., Wolfe, R., Reid, C. M., Kirpach, B., Shah, R. C., Ives, D. G., Storey, E., et al. (2018) · New England Journal of Medicine · doi:10.1056/nejmoa1803955 · Cited by 813 · cited 1×
“Moreover, the results of the Aspirin in Reducing Events in the Elderly trial showed an increased risk of cancer-related mortality in the aspirin group [14].”
ResultCook, N. R., Lee, I.-M., Gaziano, J. M., Gordon, D., Ridker, P. M., Manson, J. E., Hennekens, C. H., & Buring, J. E. (2005) · JAMA · doi:10.1001/jama.294.1.47 · Cited by 796
Research works printed but not linked: 1
- Gann PH, Manson JE, Glyn RJ, Buring JE, Hennekens CH. Low-dose aspirin and incidence of colorectal tumors in a randomised trial. J Natl Cancer Inst. 1993;85:1220–4. · DOI · Paper page
Cited by
Benjamin, D. J., Haslam, A., & Prasad, V. (2024) · Cancer Medicine · doi:10.1002/cam4.7049 · Cited by 30
Aiad, M., Tahir, A., Fresco, K., Prenatt, Z., Ramos-Feliciano, K., Walia, J., Stoltzfus, J. C., & Albandar, H. J. (2022) · Cureus · doi:10.7759/cureus.25891 · Cited by 17
Role of aspirin in cancer prevention
Sun, M., Yu, J., Wan, J., Dou, X., Chen, X., & Ye, F. (2025) · Cancer Treatment and Research Communications · doi:10.1016/j.ctarc.2025.100884 · Cited by 11
Cai, R., Liao, X., Gao, L., Xiang, J., Ye, Q., Chen, M., & Feng, S. (2023) · World Journal of Surgical Oncology · doi:10.1186/s12957-023-03247-8 · Cited by 5
“…cancer, Chuang et al. in a large retrospective study with 38,842 inoperable NSCLC patients found the use of aspirin correlated with improved OS [26]; Kanda et al. in a study with 217 stages IIIB and IV NSCLC patients also found the use of loxoprofen sodium that could extend the survival in…”
BackgroundPlatelet inhibition delays cerebral metastasis in non-small cell lung cancer
Wasilewski, D., Onken, J., Won, S., Rafaelian, A., Hempelmann, A., Bernstock, J. D., Maletzki, C., Freiman, T. M., Vajkoczy, P., Gessler, F. A., et al. (2025) · Brain and Spine · doi:10.1016/j.bas.2025.105475
Metadata
- Authors
- Chuang, M.-C., Yang, Y.-H., Hsieh, M.-J., Lin, Y.-C., Yang, T.-M., Chen, P.-C., & Hung, M.-S.
- Affiliations
- Chang Gung University (TW)
- National Taiwan University (TW)
- Chang Gung University of Science and Technology (TW)
- Corresponding author
- Hung, Ming-Szu
- ORCID
- Venue
- BMC Cancer
- Published
- 2021-11-22
- Volume
- 21
- Issue
- 1
- Pages
- 1257-1257
- ISSN
- 1471-2407 (ISSN-L)
- PMC
- PMC8607685
- OpenAlex
- W3217003007
- Cited by
- 9
- References
- 50
- Citations by year
- 2026: 2 · 2025: 4 · 2024: 1 · 2023: 1 · 2022: 1
- FWCI
- 0.44
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- cc-by
- creativecommons.org/licenses/by/4.0 (tdm)
- creativecommons.org/licenses/by/4.0 (vor)
- Locations
- BMC Cancer (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- Funders
- Chang Gung Medical Foundation
- Topics
- Health Sciences › Medicine › Pharmacology (medical) › Inflammatory mediators and NSAID effects
- Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Lung Cancer Diagnosis and Treatment
- Health Sciences › Medicine › Oncology › Lung Cancer Research Studies
- Keywords
- aspirin, non-small cell lung cancer, inoperable lung cancer, overall survival, mortality, chemoprevention, nonsteroidal anti-inflammatory drugs
- MeSH terms
- Age Factors, Aged, Anti-Inflammatory Agents, Non-Steroidal, Antineoplastic Agents, Aspirin, Carcinoma, Non-Small-Cell Lung, Female, Humans, Income, Lung Neoplasms, Male, Middle Aged, National Health Programs, Retrospective Studies, Sex Factors, Taiwan, Urbanization, Cohort Studies, Confidence Intervals, Proportional Hazards Models, Propensity Score
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: The association of aspirin use with overall survival of patients with inoperable non-small cell lung cancer: a retrospective study. https://app.cochat.ai/papers/10.1186/s12885-021-08999-8
- The paper
- Chuang, M.-C., Yang, Y.-H., Hsieh, M.-J., Lin, Y.-C., Yang, T.-M., Chen, P.-C., & Hung, M.-S. (2021). The association of aspirin use with overall survival of patients with inoperable non-small cell lung cancer: a retrospective study. BMC Cancer. https://doi.org/10.1186/s12885-021-08999-8
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.